# Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)

> **NCT03332173** · PHASE2 · COMPLETED · sponsor: **BeiGene** · enrollment: 44 (actual)

## Conditions studied

- Waldenström's Macroglobulinemia (WM)

## Interventions

- **DRUG:** Zanubrutinib

## Key facts

- **NCT ID:** NCT03332173
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-31
- **Primary completion:** 2019-05-08
- **Final completion:** 2021-01-11
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2024-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03332173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03332173, "Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03332173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*